Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 143

1.

Virological response and safety outcomes in therapy-nai ve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study.

Gish RG, Arora S, Rajender Reddy K, Nelson DR, O'Brien C, Xu Y, Murphy B.

J Hepatol. 2007 Jul;47(1):51-9. Epub 2007 Mar 12.

PMID:
17470380
[PubMed - indexed for MEDLINE]
2.

Early and sustained virological response in non-responders with chronic hepatitis C: a randomized open-label study of pegylated interferon-alpha-2a versus pegylated interferon-alpha-2b.

Scotto G, Fazio V, Fornabaio C, Tartaglia A, Di Tullio R, Saracino A, Angarano G.

Drugs. 2008;68(6):791-801.

PMID:
18416586
[PubMed - indexed for MEDLINE]
3.
4.

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.

Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J.

Health Technol Assess. 2004 Oct;8(39):iii-iv, 1-125. Review.

PMID:
15461877
[PubMed - indexed for MEDLINE]
Free Article
5.

Pegylated interferon alpha-2b, ribavirin and amantadine for chronic hepatitis C.

Younossi ZM, McCullough AC, Barnes DS, Post A, Ong JP, O'Shea R, Martin LM, Bringman D, Farmer D, Levinthal G, Mullen KD, Carey WD, Tavill AS, Ferguson R, Gramlich T.

Dig Dis Sci. 2005 May;50(5):970-5.

PMID:
15906777
[PubMed - indexed for MEDLINE]
6.

Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.

Chen TM, Huang PT, Tsai MH, Lin LF, Liu CC, Ho KS, Siauw CP, Chao PL, Tung JN.

J Gastroenterol Hepatol. 2007 May;22(5):669-75.

PMID:
17444854
[PubMed - indexed for MEDLINE]
7.

Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial.

Liu CH, Liu CJ, Lin CL, Liang CC, Hsu SJ, Yang SS, Hsu CS, Tseng TC, Wang CC, Lai MY, Chen JH, Chen PJ, Chen DS, Kao JH.

Clin Infect Dis. 2008 Nov 15;47(10):1260-9. doi: 10.1086/592579.

PMID:
18834319
[PubMed - indexed for MEDLINE]
Free Article
8.

The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients.

Yenice N, Mehtap O, Gümrah M, Arican N.

Turk J Gastroenterol. 2006 Jun;17(2):94-8.

PMID:
16830289
[PubMed - indexed for MEDLINE]
9.

Incidence of anaemia and impact on sustained virological response in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin.

Núñez M, Ocampo A, Aguirrebengoa K, Cervantes M, Pascual A, Echeverria S, Asensi V, Barreiro P, Garcia-Samaniego J, Soriano V; PRESCO Team.

J Viral Hepat. 2008 May;15(5):363-9. doi: 10.1111/j.1365-2893.2007.00952.x. Epub 2007 Dec 21.

PMID:
18179454
[PubMed - indexed for MEDLINE]
10.
11.

Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4.

El Makhzangy H, Esmat G, Said M, Elraziky M, Shouman S, Refai R, Rekacewicz C, Gad RR, Vignier N, Abdel-Hamid M, Zalata K, Bedossa P, Pol S, Fontanet A, Mohamed MK.

J Med Virol. 2009 Sep;81(9):1576-83. doi: 10.1002/jmv.21570.

PMID:
19626613
[PubMed - indexed for MEDLINE]
12.

Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen.

Crespo M, Mira JA, Pineda JA, Van den Eynde E, Ríos-Villegas MJ, Collado A, Girón-González JA, López-Cortés LF, González-Serrano M, Rivero A, Merino D, Esteban JI.

J Antimicrob Chemother. 2008 Oct;62(4):793-6. doi: 10.1093/jac/dkn262. Epub 2008 Jun 21.

PMID:
18567911
[PubMed - indexed for MEDLINE]
Free Article
13.

Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.

Bronowicki JP, Ouzan D, Asselah T, Desmorat H, Zarski JP, Foucher J, Bourlière M, Renou C, Tran A, Melin P, Hézode C, Chevalier M, Bouvier-Alias M, Chevaliez S, Montestruc F, Lonjon-Domanec I, Pawlotsky JM.

Gastroenterology. 2006 Oct;131(4):1040-8. Epub 2006 Jul 24.

PMID:
17030174
[PubMed - indexed for MEDLINE]
14.

Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial.

Jensen DM, Marcellin P, Freilich B, Andreone P, Di Bisceglie A, Brandão-Mello CE, Reddy KR, Craxi A, Martin AO, Teuber G, Messinger D, Thommes JA, Tietz A.

Ann Intern Med. 2009 Apr 21;150(8):528-40.

PMID:
19380853
[PubMed - indexed for MEDLINE]
15.

Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.

Angelico M, Koehler-Horst B, Piccolo P, Angelico F, Gentile S, Francioso S, Tarquini P, Vecchia RD, Ponti L, Pilleri G, Barlattani A, Grieco A, Soccorsi F, Guarascio P, Demelia L, Sorbello O, Rossi Z, Forlini G, Zaru S, Bandiera F; SMIEC II Investigators.

Eur J Gastroenterol Hepatol. 2008 Jul;20(7):680-7. doi: 10.1097/MEG.0b013e3282f5196c.

PMID:
18679072
[PubMed - indexed for MEDLINE]
16.

Pegylated interferon alpha-2a and ribavirin combination therapy in HCV liver transplant recipients. Experience of 7 cases.

Iacob S, Gheorghe L, Hrehoret D, Becheanu G, Herlea V, Popescu I.

J Gastrointestin Liver Dis. 2008 Jun;17(2):165-72.

PMID:
18568137
[PubMed - indexed for MEDLINE]
Free Article
17.

Peginterferon alfa-2a/ribavirin in hepatitis C virus patients nontolerant or nonresponsive to peginterferon alfa-2b/ribavirin.

Rustgi VK, Esposito S, Hamzeh FM, Shiffman ML.

Aliment Pharmacol Ther. 2008 Mar 1;27(5):433-40. Epub 2007 Dec 10.

PMID:
18081737
[PubMed - indexed for MEDLINE]
Free Article
18.

Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection.

Ascione A, De Luca M, Tartaglione MT, Lampasi F, Di Costanzo GG, Lanza AG, Picciotto FP, Marino-Marsilia G, Fontanella L, Leandro G.

Gastroenterology. 2010 Jan;138(1):116-22. doi: 10.1053/j.gastro.2009.10.005. Epub 2009 Oct 20.

PMID:
19852964
[PubMed - indexed for MEDLINE]
19.

Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.

Antonini MG, Babudieri S, Maida I, Baiguera C, Zanini B, Fenu L, Dettori G, Manno D, Mura MS, Carosi G, Puoti M.

Infection. 2008 Jun;36(3):250-5. doi: 10.1007/s15010-007-7132-6. Epub 2008 May 3.

PMID:
18458815
[PubMed - indexed for MEDLINE]
20.

Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.

Escudero A, Rodríguez F, Serra MA, Del Olmo JA, Montes F, Rodrigo JM.

J Gastroenterol Hepatol. 2008 Jun;23(6):861-6. doi: 10.1111/j.1440-1746.2008.05397.x. Epub 2008 Apr 19.

PMID:
18422960
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk